MSLE

Satellos Bioscience Inc.

Price Chart

Latest Quote

$5.55

-0.12 (-2.12%)

Current Price

Previous Close	$5.67
Open	$5.57
Day High	$5.60
Day Low	$5.50
Volume	13,490

Fetched: 2026-06-24T14:47:54

Stock Information

Shares Outstanding	20.83M
Cash Equivalents	$69.91M
Net Income	$-28.50M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$115.61M
EPS (TTM)	$-1.79
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$48.20M
Income	$-28.50M
Book/sh	$3.39
Cash/sh	$3.36
Employees	18

Financial Ratios

Quick Ratio	15.48
Current Ratio	16.48

Returns & Margins

ROA	-31.38%
ROE	-50.74%

Ownership

Insider Ownership	6.49%
Institutional Ownership	50.63%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.95
P/B	1.64

Analyst Data

Recommendation	none
Target Price	$27.67

Technical Indicators

SMA20	$6.17
SMA50	$6.94
SMA200	$7.37
RSI	38.55
ATR	0.3514

Shares Float	17.65M
Short Ratio	2.45
Volatility	1.17
Rel Volume	0.41

Performance History

Week	-3.48%
Month	-17.78%
Quarter	-21.50%
6 Months	-3.65%
YTD	-10.54%
Year	+15.91%
3 Years	+19.51%
5 Years	-70.35%
10 Years	-7.50%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$5.55	13,490
2026-06-23	$5.67	44,300
2026-06-22	$5.79	26,300
2026-06-18	$5.71	26,600
2026-06-17	$5.85	19,400
2026-06-16	$5.75	47,000
2026-06-15	$5.75	13,700
2026-06-12	$5.75	39,400
2026-06-11	$5.90	12,400
2026-06-10	$5.88	42,400
2026-06-09	$6.38	42,600
2026-06-08	$6.08	33,100
2026-06-05	$5.62	36,900
2026-06-04	$6.01	53,300
2026-06-03	$6.12	71,100
2026-06-02	$6.95	27,300
2026-06-01	$7.09	31,700
2026-05-29	$7.30	47,400
2026-05-28	$7.03	7,700
2026-05-27	$7.28	15,100
2026-05-26	$6.80	13,800

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

📰 Latest News

We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate

Simply Wall St. • 2026-05-18T13:36:01Z

Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More

24/7 Wall St. • 2026-04-06T11:54:28Z

Satellos Bioscience: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-27T13:15:02Z

Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference

MT Newswires • 2026-03-10T12:12:09Z

Satellos price target raised to $40 from $5 at Oppenheimer

TipRanks • 2026-02-11T13:12:15Z

Satellos Closes US$57.2 Million Public Offering in Canada and the United States

MT Newswires • 2026-02-09T22:30:45Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Reconciled Cost Of Revenue	-	-	-	-
Cost Of Revenue	-	-	-	-
Expenses
Total Expenses	$26,459,000	$20,398,000	$11,656,113	$6,209,844
Other Income Expense	$398,000	$-1,239,000	$-1,192,522	$-2,175,066
Net Non Operating Interest Income Expense	$1,360,000	$1,003,000	$871,401	$46,419
Operating Expense	$26,459,000	$20,398,000	$11,656,113	$6,209,844
Other Operating Expenses	$590,000	$572,000	$437,208	$292,514
General And Administrative Expense	$7,438,000	$5,452,000	$4,567,315	$2,917,772
Interest Expense	-	$0	$133,424	$0
Interest Expense Non Operating	-	$0	$133,424	$0
Other Non Operating Income Expenses	-	-	-	$-35,862
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Net Interest Income	$1,360,000	$1,003,000	$871,401	$46,419
Interest Income	$1,360,000	$1,003,000	$1,004,824	$46,419
Normalized Income	$-25,211,300	$-19,395,000	$-10,784,713	$-6,737,194
Net Income From Continuing And Discontinued Operation	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Net Income Common Stockholders	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Net Income	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Net Income Including Noncontrolling Interests	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Net Income Continuous Operations	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Pretax Income	$-24,701,000	$-20,634,000	$-11,977,235	$-8,338,491
Special Income Charges	$0	$-2,905,000	$-321,122	$-2,125,700
Interest Income Non Operating	$1,360,000	$1,003,000	$1,004,824	$46,419
Operating Income	$-26,459,000	$-20,398,000	$-11,656,113	$-6,209,844
Depreciation Amortization Depletion Income Statement	$5,000	$15,000	$5,277	$248,305
Depreciation And Amortization In Income Statement	$5,000	$15,000	$5,277	$248,305
Depreciation Income Statement	$5,000	$15,000	$5,277	$2,947
Total Operating Income As Reported	-	$-19,375,832	$-11,656,113	$-6,209,844
Amortization Of Intangibles Income Statement	-	-	$0	$245,358
Gross Profit	-	-	-	-
Per Share
Diluted EPS	$-1.70	$-2.16	$-1.63	$-2.83
Basic EPS	$-1.70	$-2.16	$-1.63	$-2.83
Other
Tax Effect Of Unusual Items	$59,700	$0	$0	$-570,085
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-26,852,000	$-19,144,000	$-10,646,012	$-5,915,119
Total Unusual Items	$398,000	$-1,239,000	$-1,192,522	$-2,175,066
Total Unusual Items Excluding Goodwill	$398,000	$-1,239,000	$-1,192,522	$-2,175,066
Reconciled Depreciation	$4,000	$15,000	$5,277	$248,305
EBITDA (Bullshit earnings)	$-26,454,000	$-20,383,000	$-11,838,535	$-8,090,186
EBIT	$-26,459,000	$-20,398,000	$-11,843,811	$-8,338,491
Diluted Average Shares	$14,595,771	$9,564,861	$7,200,396	$2,973,342
Basic Average Shares	$14,595,771	$9,564,861	$7,200,396	$2,973,342
Diluted NI Availto Com Stockholders	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Tax Provision	$172,000	$0	$0	$3,684
Impairment Of Capital Assets	$0	$2,905,000	$0	$2,125,700
Gain On Sale Of Security	$398,000	$1,666,000	$-871,401	$-49,366
Research And Development	$18,426,000	$14,359,000	$6,646,314	$2,751,253
Selling General And Administration	$7,438,000	$5,452,000	$4,567,315	$2,917,772
Other Gand A	$2,374,000	$1,688,000	$1,837,781	$1,173,003
Salaries And Wages	$5,064,000	$3,764,000	$2,729,534	$1,744,769
Other Special Charges	-	-	$321,122	-
Amortization	-	-	$0	$245,358
Restructuring And Mergern Acquisition	-	-	-	$0
Insurance And Claims	-	-	-	$25,268

Fetched: 2026-06-23

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$27,784,000	$47,164,000	$30,756,000	$-403,036
Total Assets	$31,889,000	$50,747,000	$33,490,000	$4,567,492
Total Non Current Assets	$5,000	$4,000	$3,007,000	$2,922,930
Goodwill And Other Intangible Assets	$0	$0	$2,961,000	$2,885,352
Current Assets	$31,884,000	$50,743,000	$30,483,000	$1,645,299
Hedging Assets Current	$0	$0	$3,000	$2,210
Prepaid Assets	$3,804,000	$1,760,000	$112,000	$33,893
Receivables	$370,000	$435,000	$441,000	$191,571
Taxes Receivable	$370,000	$435,000	$441,000	$191,571
Cash Cash Equivalents And Short Term Investments	$27,710,000	$48,548,000	$29,927,000	$1,417,625
Cash And Cash Equivalents	$9,804,000	$40,073,000	$16,681,000	$1,417,625
Cash Equivalents	$5,420,000	$15,688,000	$16,175,185	$818,597
Cash Financial	$4,384,000	$24,385,000	$459,068	$599,027
Other Non Current Assets	-	-	$2,992,000	-
Other Intangible Assets	-	-	-	$3,916,190
Accounts Receivable	-	-	-	$0
Liabilities
Total Liabilities Net Minority Interest	$4,105,000	$3,583,000	$2,734,000	$2,085,175
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$0
Current Liabilities	$4,105,000	$3,583,000	$2,734,000	$2,085,175
Payables And Accrued Expenses	$4,105,000	$3,583,000	$2,734,000	$2,085,175
Payables	$1,844,000	$2,063,000	$783,959	$1,080,165
Total Tax Payable	$72,000	$0	-	-
Income Tax Payable	$72,000	$0	-	-
Accounts Payable	$1,772,000	$2,063,000	$783,959	$1,080,165
Equity
Common Stock Equity	$27,784,000	$47,164,000	$30,756,000	$2,482,317
Total Equity Gross Minority Interest	$27,784,000	$47,164,000	$30,756,000	$2,482,317
Stockholders Equity	$27,784,000	$47,164,000	$30,756,000	$2,482,317
Other Equity Interest	$15,480,000	$19,967,000	$13,050,000	$804,598
Gains Losses Not Affecting Retained Earnings	$-1,720,000	$-1,737,000	$362,000	$-5,158
Other Equity Adjustments	$-1,720,000	$-1,737,000	$362,000	$-5,158
Retained Earnings	$-81,970,000	$-57,097,000	$-36,463,000	$-23,292,809
Other
Ordinary Shares Number	$15,458,929	$13,818,322	$9,399,304	$3,483,134
Share Issued	$15,458,929	$13,818,322	$9,399,304	$3,483,134
Tangible Book Value	$27,784,000	$47,164,000	$30,756,000	$-403,036
Invested Capital	$27,784,000	$47,164,000	$30,756,000	$2,482,317
Working Capital	$27,779,000	$47,160,000	$27,749,000	$-439,876
Total Capitalization	$27,784,000	$47,164,000	$30,756,000	$2,482,317
Additional Paid In Capital	$10,166,000	$7,900,000	$6,472,000	$2,717,359
Capital Stock	$85,828,000	$78,131,000	$47,335,000	$22,258,326
Common Stock	$85,828,000	$78,131,000	$47,335,000	$22,258,326
Current Accrued Expenses	$2,261,000	$1,520,000	$1,947,837	$1,005,010
Investments And Advances	$0	$0	$31,000	$30,946
Net PPE	$5,000	$4,000	$15,000	$6,631
Other Short Term Investments	$17,906,000	$8,475,000	$13,246,000	-
Gross PPE	-	$3,484	$14,322	$10,315
Other Properties	-	$3,484	$14,322	-
Accumulated Depreciation	-	-	$-13,000	$-3,684
Machinery Furniture Equipment	-	-	$32,000	$10,315

Fetched: 2026-06-23

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-23,602,000	$-18,256,000	$-8,746,419	$-4,263,189
Operating Activities
Operating Cash Flow	$-23,596,000	$-18,252,000	$-8,732,851	$-4,260,978
Cash Flow From Continuing Operating Activities	$-23,596,000	$-18,252,000	$-8,732,851	$-4,157,825
Operating Gains Losses	$-484,000	$-1,068,000	$1,192,522	$18,420
Investing Activities
Capital Expenditure	$-6,000	$-4,000	$-13,569	$-2,210
Investing Cash Flow	$-9,417,000	$4,656,000	$-13,220,262	$-2,210
Cash Flow From Continuing Investing Activities	$-9,417,000	$4,656,000	$-13,220,262	$-2,210
Net Other Investing Changes	-	-	-	-
Financing Activities
Issuance Of Capital Stock	$0	$30,057,000	$24,470,828	$2,044,651
Financing Cash Flow	$2,241,000	$37,574,000	$38,013,719	$2,044,651
Cash Flow From Continuing Financing Activities	$2,241,000	$37,574,000	$38,147,143	$2,044,651
Net Common Stock Issuance	$0	$30,057,000	$24,470,828	$2,044,651
Common Stock Issuance	$0	$30,057,000	$24,470,828	$2,044,651
Net Other Financing Charges	-	-	$454,545	-
Cash Dividends Paid	-	-	$0	$0
Other
End Cash Position	$9,804,000	$40,073,000	$16,634,253	$1,417,625
Beginning Cash Position	$40,073,000	$16,681,000	$1,450,324	$3,589,007
Effect Of Exchange Rate Changes	$503,000	$-586,000	$-876,677	$-55,998
Changes In Cash	$-30,772,000	$23,978,000	$16,060,606	$-2,115,385
Proceeds From Stock Option Exercised	$2,241,000	$7,517,000	$13,827,831	$0
Net Investment Purchase And Sale	$-9,411,000	$4,660,000	$-13,206,694	$0
Sale Of Investment	$13,958,000	$32,076,000	$0	-
Purchase Of Investment	$-23,369,000	$-27,416,000	$-13,206,694	$0
Net PPE Purchase And Sale	$-6,000	$-4,000	$-13,569	$-2,210
Purchase Of PPE	$-6,000	$-4,000	$-13,569	$-2,210
Change In Working Capital	$-1,478,000	$-753,000	$278,155	$730,180
Change In Payables And Accrued Expense	$501,000	$1,012,000	$598,523	$534,925
Change In Prepaid Assets	$-2,044,000	$-1,733,000	$-76,888	$-1,474
Change In Receivables	$65,000	$-32,000	$-243,480	$196,729
Stock Based Compensation	$3,235,000	$1,641,000	$1,635,007	$1,061,008
Asset Impairment Charge	$0	$2,905,000	$0	$2,126,437
Depreciation Amortization Depletion	$4,000	$15,000	$5,277	$248,305
Depreciation And Amortization	$4,000	$15,000	$5,277	$248,305
Depreciation	$4,000	$15,000	$5,277	$2,947
Net Foreign Currency Exchange Gain Loss	$-484,000	$-1,071,000	$872,154	$51,577
Net Income From Continuing Operations	$-24,873,000	$-20,634,000	$-11,977,235	$-8,342,175
Repayment Of Debt	-	$0	$-1,976,481	$0
Issuance Of Debt	-	$0	$1,691,542	$0
Net Issuance Payments Of Debt	-	$0	$-284,939	$0
Net Long Term Debt Issuance	-	$0	$-284,939	$0
Long Term Debt Payments	-	$0	$-1,976,481	$0
Long Term Debt Issuance	-	$0	$1,691,542	$0
Other Non Cash Items	-	$-358,000	$133,424	$-103,154
Gain Loss On Investment Securities	-	$3,000	$-754	$-33,156
Interest Paid Cff	-	-	$-70,104	$0
Amortization Cash Flow	-	-	$0	$245,358
Amortization Of Intangibles	-	-	$0	$245,358
Net Business Purchase And Sale	-	-	-	$0
Sale Of Business	-	-	-	$0
Changes In Account Receivables	-	-	-	$1,314

Fetched: 2026-06-23